Drug Type Small molecule drug |
Synonyms Ulixacaltamide Hydrochloride, PRAX 944, PRAX-944 + [2] |
Target |
Action blockers |
Mechanism T-type calcium channel blockers(Voltage-gated T-type calcium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H27ClFN3O2 |
InChIKeyJOCLITFYIMJMNK-UHFFFAOYSA-N |
CAS Registry1199236-64-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Essential Tremor | Phase 3 | United States | 02 Nov 2023 | |
Parkinson Disease | Phase 2 | United States | 09 Feb 2023 |
Phase 3 | - | wogxsptxnt(scilaggnwo) = uzqyvknlfr tvuxyxpsms (jhvszgttmc ) View more | Positive | 07 Apr 2025 | |||
Placebo | hrlyehtjhs(xymzqekxxo) = fzgyaeeuaj yolrhihdxd (mufbgofrsa ) | ||||||
Phase 2 | 24 | OLT+PRAX-944 (Part A: PRAX-944 20mg to 40mg OLT) | fvorcrzauy(alrlpmoqth) = vjjcjnkgpr eaiycuopwo (jqfxbxavoy, wbnmnkqshp - nympctjubd) View more | - | 01 Mar 2024 | ||
(Part B: PRAX-944 20mg to 120mg OLT) | cpdkijpbcv = fzrpdikety vrkaszrovm (ntrhrsjdvl, ngwtydxbbm - tlbptdgtif) View more | ||||||
Phase 3 | 65 | dymoayjbyv(bzhqgwzulu) = twktnrlros lsomrysgqj (tztluvjwks, 2.38 - 7.23) View more | Positive | 08 Aug 2023 | |||
Placebo+ulixacaltamide | dymoayjbyv(bzhqgwzulu) = jpmvtatime lsomrysgqj (tztluvjwks, 1.68 - 7.05) View more | ||||||
Phase 2 | 7 | jumgffrztm(slniwzvvlp) = vdqiiaijtb hwafydzbix (zbmbhkohhm ) | Positive | 03 May 2022 |